The estimated Net Worth of David J. Marguglio is at least $1.89 Milhão dollars as of 18 March 2022. Mr. Marguglio owns over 11,859 units of Adamis Pharmaceuticals Corp stock worth over $180,108 and over the last 14 years he sold ADMP stock worth over $742,167. In addition, he makes $966,788 as Senior Vice President e Chief Business Officer and Director at Adamis Pharmaceuticals Corp.
David has made over 33 trades of the Adamis Pharmaceuticals Corp stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 11,859 units of ADMP stock worth $7,115 on 18 March 2022.
The largest trade he's ever made was selling 50,757 units of Adamis Pharmaceuticals Corp stock on 1 December 2021 worth over $40,098. On average, David trades about 6,814 units every 63 days since 2010. As of 18 March 2022 he still owns at least 233,906 units of Adamis Pharmaceuticals Corp stock.
You can see the complete history of Mr. Marguglio stock trades at the bottom of the page.
David J. Marguglio serves as Senior Vice President, Chief Business Officer and Director of the Company. Mr. Marguglio joined the Company as Vice President, Business Development and Investor Relations, and a director in April 2009 in connection with the closing of the merger transaction with Old Adamis, and has held positions with the Company of Senior Vice President of Corporate Development and, since March 2017, Senior Vice President and Chief Business Officer. Mr. Marguglio was a co-founder of Old Adamis and served as its Vice President of Business Development and Investor Relations, and a director, since its inception in June 2006 until April 2009. From 1996 to 2006, he held various positions with Citigroup Global Markets, Smith Barney and Merrill Lynch. Before entering the financial industry, from 1994 to 1996, he founded and ran two different startup companies, the latter of which was eventually acquired by a Fortune 100 company. From 1993 to 1994, he served as financial counsel for the commercial litigation division of a national law firm. He received a degree in finance and business management from the Hankamer School of Business at Baylor University.
As the Senior Vice President e Chief Business Officer and Director of Adamis Pharmaceuticals Corp, the total compensation of David Marguglio at Adamis Pharmaceuticals Corp is $966,788. There are 4 executives at Adamis Pharmaceuticals Corp getting paid more, with Dennis Carlo having the highest compensation of $1,770,310.
David Marguglio is 49, he's been the Senior Vice President e Chief Business Officer and Director of Adamis Pharmaceuticals Corp since 2010. There are 12 older and 1 younger executives at Adamis Pharmaceuticals Corp. The oldest executive at Adamis Pharmaceuticals Corp is Dr. Dennis J. Carlo, 78, who is the Pres, CEO & Director.
David's mailing address filed with the SEC is 11455 El Camino Real # 310, San Diego, CA 92130, USA.
Over the last 14 years, insiders at Adamis Pharmaceuticals Corp have traded over $2,051,720 worth of Adamis Pharmaceuticals Corp stock and bought 87,550 units worth $188,843 . The most active insiders traders include Ahmed Shayan Fazlur Eses Ho..., Dennis J Phd Carlo, eDavid J. Marguglio. On average, Adamis Pharmaceuticals Corp executives and independent directors trade stock every 34 days with the average trade being worth of $12,919. The most recent stock trade was executed by Dennis J Phd Carlo on 25 May 2022, trading 250,000 units of ADMP stock currently worth $192,500.
adamis pharmaceuticals corporation (nasdaq: admp) is a specialty biopharmaceuticals company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergies, oncology and immunology. its specialty pharmaceutical division currently has four products in its pipeline including the epinephrine injection pre-filled syringe (pfs) for use in the emergency treatment of anaphylaxis, apc-1000 and apc-5000 (dry powder inhaler) for the treatment of asthma and chronic obstructive pulmonary disease (copd), and apc-3000, a hydrofluoroalkane (hfa) inhaled nasal steroid product for the treatment of allergic rhinitis. this division’s focus is to create low cost therapeutic alternatives to existing treatments in large markets. adamis will pursue 505(b)(2) regulatory approval filings in order to minimize costs and shorten the time to market in this division. within its biotechnology division, the company has four products under development include telob-vax, a
Adamis Pharmaceuticals Corp executives and other stock owners filed with the SEC include: